Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Format: Artigo
Langue:Inglês
Publié: European Respiratory Society 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3485572/
https://ncbi.nlm.nih.gov/pubmed/23060624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/09031936.00040712
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires